Role of Sertoli and Leydig Cells in the Regulation of Spermatogonial Stem Cell and Development of Reproductive Disorders in Male C57Bl/6 Mice with Type 1 Diabetes Mellitus


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Course administration streptozotocin to male C57Bl/6 mice induces a complex of symptoms typical of type 1 diabetes mellitus: hyperglycemia and insulin deficiency, focal inflammatory infiltration of the pancreas, destructive changes in the Langerhans islets, damage to the insular apparatus (reduced number of PDX1+ cells and insulin expression by the secreting cells). Male reproductive disorder are serious complications of type 1 diabetes mellitus. In “diabetic” mice, interstitial edema with inflammatory infiltration and microvascular disorders in the testicular tissue are observed, the number of endothelial precursors (CD45/CD31+) and the total number and percentage of motile spermatozoa decreased, immature spermatogenic epithelium cells are desquamated of into the lumen of the tubules. Disturbances in the proliferation and differentiation of various spermatogonial stem cell populations (c-kit/CD90+, c-kit+/CD90+, and CD51/CD24+/CD52+) in diabetes can be explained by the inhibitory influence of inflammatory factors on testosterone-producing Leydig cells.

About the authors

E. G. Skurikhin

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine

Email: angelinapakhomova2011@gmail.com
Russian Federation, Tomsk

A. V. Pakhomova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine

Author for correspondence.
Email: angelinapakhomova2011@gmail.com
Russian Federation, Tomsk

O. V. Pershina

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine

Email: angelinapakhomova2011@gmail.com
Russian Federation, Tomsk

V. A. Krupin

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine

Email: angelinapakhomova2011@gmail.com
Russian Federation, Tomsk

N. N. Ermakova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine

Email: angelinapakhomova2011@gmail.com
Russian Federation, Tomsk

E. S. Pan

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine

Email: angelinapakhomova2011@gmail.com
Russian Federation, Tomsk

A. I. Kudryashova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine

Email: angelinapakhomova2011@gmail.com
Russian Federation, Tomsk

L. A. Ermolaeva

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine

Email: angelinapakhomova2011@gmail.com
Russian Federation, Tomsk

E. S. Khmelevskaya

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine

Email: angelinapakhomova2011@gmail.com
Russian Federation, Tomsk

V. E. Goldberg

Tomsk National Research Medical Centre, Russian Academy of Sciences

Email: angelinapakhomova2011@gmail.com
Russian Federation, Tomsk

V. V. Zhdanov

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine

Email: angelinapakhomova2011@gmail.com
Russian Federation, Tomsk

A. M. Dygai

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine

Email: angelinapakhomova2011@gmail.com
Russian Federation, Tomsk


Copyright (c) 2017 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies